Drug Trial Radar · NCT04215978
Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Oct 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
204
Actual
Start
Jan 30, 2020
Primary completion
Jan 24, 2025
Study completion Jan 24, 2025
Sponsor
- Lead sponsor
- BeiGeneBeOne Medicines (BeiGene) (ONC)
- Sponsor type
- Industry
- First posted
- Jan 2, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and tolerability of BGB-A445 alone and in combination with tislelizumab in participants with advanced solid tumors; and to determine the maximum tolerated dose(s) (MTD) or maximum administered dose(s) (MAD) and recommended Phase 2 doses (RP2D) of BGB-A445 alone and in combination with tislelizumab.
Conditions
- Advanced Solid Tumor
- Non Small Cell Lung Cancer
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Nasopharyngeal Carcinoma (NPC)
Interventions
BGB-A445Drug
Administered as specified in the treatment arm
tislelizumabDrug
Administered as specified in the treatment arm
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1a: Number of Participants Experiencing Adverse Events (AEs)Time frame: Up to 90 days after the last dose of study drug(s) regardless of whether the participant starts a subsequent anticancer therapy
- Phase 1a: Number of Participants Experiencing Serious Adverse Events (SAEs)Time frame: Up to 90 days after the last dose of study drug(s) regardless of whether the participant starts a subsequent anticancer therapy
- Phase 1a: Number of Participants Experiencing AEs meeting protocol defined Dose-Limiting Toxicity (DLT) criteriaTime frame: Up to 90 days after the last dose of study drug(s) regardless of whether the participant starts a subsequent anticancer therapy
- Phase 1a: Maximum Tolerated Dose (MTD) of BGB-A445Time frame: Up to 30 days after the last dose of study drug(s) or before the initiation of a new anticancer treatment, whichever occurs first
- Phase 1b: RP2D of BGB-A445 when Administered AloneTime frame: Up to 30 days after the last dose of study drug(s) or before the initiation of a new anticancer treatment, whichever occurs first
- Phase 1b: Overall Response Rate (ORR) as Assessed by the InvestigatorTime frame: Up to 30 days after the last dose of study drug(s) or before the initiation of a new anticancer treatment, whichever occurs first
Locations
30 sites in 8 countries. Site status is shown where the registry gives one.
Valkyrie Clinical Trials
Los Angeles, California
California Cancer Associates for Research & Excellence (cCARE)
San Diego, California
UPMC Hillman Cancer Center (Univ Of Pittsburgh)
Pittsburgh, Pennsylvania
Blacktown Cancer And Haematology Centre
Blacktown, New South Wales, Australia
Pindara Private Hospital
Benowa, Queensland, Australia
Princess Alexandra Hospital
Brisbane, Queensland, Australia
Monash Health
Clayton, Victoria, Australia
Peter Maccallum Cancer Centre
Melbourne, Victoria, Australia
Nucleus Network
Melbourne, Victoria, Australia
Linear Clinical Research
Nedlands, Western Australia, Australia
Union Hospital Of Tongji Medical College, Huazhong University Of Science And Technology
Wuhan, Hubei, China
The Second Xiangya Hospital Of Central South University
Changsha, Hunan, China
Jinan Central Hospital
Jinan, Shandong, China
Linyi Cancer Hospital
Linyi, Shandong, China
Affiliated Zhongshan Hospital Of Fudan University
Shanghai, Shanghai Municipality, China
Sir Run Run Shaw Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
University of Malaya Medical Centre
Kuala Lumpur, Malaysia
Sarawak General Hospital
Kuching, Malaysia
Auckland City Hospital
Auckland, New Zealand
National Cancer Center (NCC)
Goyang-si, Gyeonggi-do, South Korea
Cha Bundang Medical Center, Cha University
Gyeonggido, Gyeonggi-do, South Korea
The Catholic University of Korea, St. Vincent's Hospital
Suwon, Gyeonggi-do, South Korea
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggido, South Korea
Severance Hospital Yonsei University Health System
Seoul, Seoul Teugbyeolsi, South Korea
National Cheng Kung University Hospital
Tainan, Taiwan
Changhua Christian Hospital
Changhua, NAP, Taiwan
King Chulalongkorn Memorial Hospital (Chulalongkorn University)
Bangkok, Thailand
Ramathibodi Hospital Mahidol University
Bangkok, Thailand
Srinagarind Hospital (Khon Kaen University)
Muang, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.